• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: AUGMENIX, INC. SPACEOAR SYSTEM; ABSORBABLE PERIRECTAL SPACER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

AUGMENIX, INC. SPACEOAR SYSTEM; ABSORBABLE PERIRECTAL SPACER Back to Search Results
Model Number SO-2101
Device Problem Positioning Problem (3009)
Patient Problems Edema (1820); Inflammation (1932); Muscle Spasm(s) (1966); Pain (1994); Ulcer (2274); Injury (2348); Fluid Discharge (2686)
Event Date 03/01/2020
Event Type  Injury  
Manufacturer Narrative
Date of event: date the article was published.Exact date of event is unknown.The complainant was unable to provide the device lot number.Therefore, the manufacture and expiration dates are unknown.Literature source: dinh, tru-khang, et al."a case of rectal ulcer during intensity modulated radiotherapy for prostate cancer using hydrogel spacer" urologypractice, vol.7, 158-161, march 1st 2020.Doi: 10.1097/upj.0000000000000071.(b)(4).The device was implanted and will not be returned for evaluation; therefore a failure analysis of the complaint device could not be completed.If any further relevant information is identified, a supplemental medwatch will be filed.
 
Event Description
Boston scientific corporation became aware of an event through the article "a case of rectal ulcer during intensity modulated radiotherapy for prostate cancer using hydrogel spacer" written by tru-khang t.Dinh, et al.A board certified urologist placed gold prostate fiducials and hydrogel rectal spacer transperineally under ultrasound guidance 19 days before starting treatment.Reportedly the procedure was performed under local anesthesia.The patient tolerated the procedure well and there were no reported complications.Pretreatment pelvic magnetic resonance imaging (mri) confirmed placement of the spacer in the perirectal space.The patient underwent a course of intensity modulated radiation therapy (imrt) using volumetric arc therapy to the prostate and proximal seminal vesicles.Rectal enema was performed before computerized tomography (ct) simulation and daily image guidance with on-board cone beam ct was used.Early in the treatment course the patient had no gastrointestinal (gi) symptoms.As radiation dose increased, the patient began noticing rectal urgency, mucous discharge and aching perirectal pain.Reportedly, there was no hematochezia.Reportedly, the pain initially improved with nonsteroidal ant-inflammatory drugs and bismuth subsalicylate, but the patient continued to have frequent bowel movements with mucous.As the radiation dose continued to increase, the patient had increasing proctitis (inflammation) consisting of rectal urgency and frequency as well as continued mucous discharge.The patient was treated with hydro-cortisone rectal suppositories with modest improvement in symptoms.The patient was able to complete treatment with stable rectal symptoms.One week after completing treatment the patient presented to the emergency department with 3 days of crescendo rectal pain, rectal urgency every 20 minutes, and spasm.Ct of the abdomen and pelvis revealed perirectal fat stranding and edema, but no anatomical defect was identified.The patient was treated conservatively with stool softeners and pain medication.Flexible sigmoidoscopy obtained after discharge from the hospital revealed an 18 mm ulcer with associated proctitis at the anterior rectal wall.Subsequent mri of the pelvis demonstrated that the ulcer was contiguous with a pseudo-lumen in the region formerly occupied by spaceoar.The patient underwent 40 daily dives of hyperbaric oxygen and experienced improvement in symptoms halfway through the treatments.By the end of this course, 3 months after completing radiotherapy, rectal symptoms had nearly returned to baseline.Repeat flexible sigmoidoscopy showed improvement in the rectal ulcer and resolution of associated proctitis.Reportedly, the patient has completely recovered, is asymptomatic and without disease.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SPACEOAR SYSTEM
Type of Device
ABSORBABLE PERIRECTAL SPACER
Manufacturer (Section D)
AUGMENIX, INC.
201 burlington road
bedford MA 01730
Manufacturer (Section G)
AUGMENIX, INC.
201 burlington road
bedford MA 01730
Manufacturer Contact
carole morley
300 boston scientific way
marlborough, MA 01752
5086834015
MDR Report Key9881066
MDR Text Key189611261
Report Number3005099803-2020-01328
Device Sequence Number1
Product Code OVB
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K181465
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,health
Reporter Occupation Physician
Type of Report Initial
Report Date 03/25/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model NumberSO-2101
Device Catalogue NumberSO-2101
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 02/28/2020
Initial Date FDA Received03/25/2020
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age69 YR
-
-